All In MedTech

Device Trial Radar · NCT04796545

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

A Prospective, Multicenter Post-marketing Clinical Investigation of the SING IMT(TM) System, Model NG SI IMT 3X in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

68

Actual

Start

Sep 13, 2022

Primary completion

May 2027

Study completion Dec 2028

Sponsor

Lead sponsor
VisionCare, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 15, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD). Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.

Conditions

  • AMD
  • Age-Related Macular Degeneration

Interventions

  • SING IMT(TM) System, model NG SI IMT 3XDevice

    The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of the SING IMT System, model NG SI IMT 3X, including its delivery systemTime frame: 12 months

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • UZ Brussel

    Brussels, Belgium

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.